<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589845</url>
  </required_header>
  <id_info>
    <org_study_id>BO41932</org_study_id>
    <secondary_id>2020-001847-16</secondary_id>
    <nct_id>NCT04589845</nct_id>
  </id_info>
  <brief_title>Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study</brief_title>
  <official_title>Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to&#xD;
      evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or&#xD;
      in rational, specified combinations in participants with unresectable, locally advanced or&#xD;
      metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who&#xD;
      are tumor mutational burden (TMB)-high as identified by a validated next-generation&#xD;
      sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug&#xD;
      regimen tailored to their NGS assay results at screening. Participants will be assigned to&#xD;
      the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on&#xD;
      the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria,&#xD;
      and, unless otherwise specified, will continue until disease progression, loss of clinical&#xD;
      benefit, unacceptable toxicity, participant or physician decision to discontinue, or death,&#xD;
      whichever occurs first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">September 25, 2032</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2032</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cohorts: Independent Review Committee (IRC)-assessed objective response rate (ORR) based on confirmed objective response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)</measure>
    <time_frame>Approximately up to 12 years</time_frame>
    <description>Confirmed objective response indicates &gt;/= 4 weeks after initial documentation of response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed duration of response (DOR) per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed clinical benefit rate (CBR) per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed progression free survival (PFS) per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed DOR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed CBR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed PFS per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC- and INV-assessed time to central nervous system (CNS) progression per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Overall Survival (OS)</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-Oncology (RANO)</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC)</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, KIRC-assessed DOR per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: IRC-assessed CBR per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: IRC-assessed PFS per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: INV-assessed ORR per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: INV-assessed DOR per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: INV-assessed CBR per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, D, E, F, H, I, J, K: INV-assessed PFS per INRC</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed ORR per RECIST v1.1 in participants with alteration/biomarker-positive circulating tumor DNA (ctDNA) by blood-based next-generation sequencing (NGS) assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed DOR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed CBR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: IRC-assessed PFS per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed ORR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed DOR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed CBR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: INV-assessed PFS per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed intracranial (IC)-ORR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS rate per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS rate per RECIST v1.1</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Percentage of participants with confirmed deterioration as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)</measure>
    <time_frame>Approximately up to 12 years</time_frame>
    <description>The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Change from Baseline in the EORTC-QLQ-C30 total score</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Percentage of participants with a clinical meaningful change on the Global Health Status, Physical Functioning, and Role Functioning scores from the EORTC QLQ-C30</measure>
    <time_frame>Approximately up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Time to confirmed symptom onset or worsening from tumor-related symptom scores from the EORTC QLQ-C30 and EORTC Item Library</measure>
    <time_frame>Approximately up to 12 years</time_frame>
    <description>The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Approximately up to 12 years</time_frame>
    <description>Adverse event severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts A, B: Plasma concentration of entrectinib at specified timepoints</measure>
    <time_frame>Day 1 of Cycle 1-6 and Day 1 of every other Cycle going forward (one Cycle=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort C: Plasma concentration of alectinib at specified timepoints</measure>
    <time_frame>Cycle 1, Day 1 and Day 15; Day 1 of Cycle 2-6, and Day 1 of every other Cycle going forward (one Cycle=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort D: Plasma concentration of atezolizumab at specified timepoints</measure>
    <time_frame>Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, and every even Cycles thereafter (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort E: Plasma concentration of ipatasertib at specified timepoints</measure>
    <time_frame>Cycle 1, Day 1 and 15; Cycle 2, Day 1; Cycle 3, Day 15; Cycle 4, Day 1, and every even Cycle thereafter (one Cycle=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort F: Serum concentration of trastuzumab emtansine at specified timepoints</measure>
    <time_frame>Cycle 1, Day 1; Cycle 2, Day 1; Cycle 4, Day 1; Cycle 6, Day 1, and every even Cycle thereafter (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort G: Plasma concentration of idasanutlin at specified timepoint</measure>
    <time_frame>Cycle 1, Day 1, 2, 5, 8; Cycle 2, Day 1, 2, 5; Cycle 3, Day 2, 5; Cycle 4, Day 1, and every other Cycle going forward (one Cycle=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort H: Plasma concentration of GDC-0077 at specified timepoints</measure>
    <time_frame>Cycle 1, Day 1, 8 (+/-1 day), 15 (+/-1 day); Cycle 2, Day 1 (+/-1 day); Day 1 of Cycle 4, and every other even Cycle going forward (one Cycle=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts D, F: Percentage of participants with anti-drug antibodies (ADA)</measure>
    <time_frame>Cohort D: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, and every even Cycles thereafter (one Cycle=21 days); Cohort F: Cycle 1, Day 1; Cycle 2, Day 1; Cycle 4, Day 1; Cycle 6, Day 1, and every even Cycle thereafter (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">770</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort A: ROS1 fusion-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) &gt;/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA&lt;1.51 m2 will be lower.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: NTRK1/2/3 fusion-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA &gt;/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA&lt;1.51 m2 will be lower.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: ALK fusion-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: TMB-high tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged &gt;/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged &lt; 18 years on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: AKT1/2/3 mutant-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants &lt;35 kg, 300 mg for participants &gt;/= 35 and &lt;45 kg, 400 mg for those &gt;/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: HER2 mutant-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G: MDM2-amplified, TP53 wild-type tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle.&#xD;
Note: Cohort G has been closed for enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H: PIK3CA multiple mutant-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort I: BRAF class II mutant or fusion-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J: BRAF class III mutant-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort K: RET fusion-positive tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and &lt; 18 years of age. A treatment cycle consists of 4 weeks (28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>Adults and pediatric participants with a BSA &gt;/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA &lt; 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).</description>
    <arm_group_label>Cohort A: ROS1 fusion-positive tumors</arm_group_label>
    <other_name>Rozlytrek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>Adults and pediatric participants with a BSA &gt;/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA &lt; 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).</description>
    <arm_group_label>Cohort B: NTRK1/2/3 fusion-positive tumors</arm_group_label>
    <other_name>Rozlytrek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).</description>
    <arm_group_label>Cohort C: ALK fusion-positive tumors</arm_group_label>
    <other_name>Alecensa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged &gt;/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged &lt;18 years on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort D: TMB-high tumors</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants &lt; 35 kg, 300 mg for participants &gt;/= 35 and &lt; 45 kg, 400 mg for those &gt;/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.</description>
    <arm_group_label>Cohort E: AKT1/2/3 mutant-positive tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab emtansine</intervention_name>
    <description>Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.</description>
    <arm_group_label>Cohort F: HER2 mutant-positive tumors</arm_group_label>
    <other_name>Kadcyla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idasanutlin</intervention_name>
    <description>Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart.&#xD;
Note: Cohort G has been closed for enrollment.</description>
    <arm_group_label>Cohort G: MDM2-amplified, TP53 wild-type tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inavolisib</intervention_name>
    <description>GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.</description>
    <arm_group_label>Cohort H: PIK3CA multiple mutant-positive tumors</arm_group_label>
    <other_name>GDC-0077</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belvarafenib</intervention_name>
    <description>Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.</description>
    <arm_group_label>Cohort I: BRAF class II mutant or fusion-positive tumors</arm_group_label>
    <arm_group_label>Cohort J: BRAF class III mutant-positive tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralsetinib</intervention_name>
    <description>Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and &lt; 18 years of age. A treatment cycle consists of 4 weeks (28 days).</description>
    <arm_group_label>Cohort K: RET fusion-positive tumors</arm_group_label>
    <other_name>Gavreto (US)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of advanced and unresectable or&#xD;
             metastatic solid malignancy&#xD;
&#xD;
          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version&#xD;
             1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or&#xD;
             International Neuroblastoma Response Criteria (INRC)&#xD;
&#xD;
          -  Performance status as follows: Participantss aged &gt;= 18 years: Eastern Cooperative&#xD;
             Oncology Group (ECOG) Performance Status 0-2; Participantss aged 16 to &lt; 18 years:&#xD;
             Karnofsky score &gt;= 50%; Participants aged &lt; 16 years: Lansky score &gt;= 50%&#xD;
&#xD;
          -  For participants aged &gt;= 18 and &lt;18 years: adequate hematologic and end-organ function&#xD;
&#xD;
          -  Disease progression on prior treatment, or previously untreated disease with no&#xD;
             available acceptable treatment&#xD;
&#xD;
          -  Adequate recovery from most recent systemic or local treatment for cancer&#xD;
&#xD;
          -  Life expectancy &gt;= 8 weeks&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the investigator's judgment&#xD;
&#xD;
          -  For female participants of childbearing potential: Negative serum pregnancy test &lt;= 14&#xD;
             days prior to initiating study treatment; agreement to remain abstinent or use single&#xD;
             or combined contraception methods that result in a failure rate of &lt; 1% per year for&#xD;
             the period defined in the cohort-specific inclusion criteria; and agreement to refrain&#xD;
             from donating eggs during the same period&#xD;
&#xD;
          -  For male participants: Willingness to remain abstinent or use acceptable methods of&#xD;
             contraception as defined in the cohort-specific inclusion criteria&#xD;
&#xD;
          -  In addition to the general inclusion criteria above, participants must meet all of the&#xD;
             cohort-specific inclusion criteria for the respective cohort&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current participation or enrollment in another therapeutic clinical trial&#xD;
&#xD;
          -  Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study&#xD;
             treatment&#xD;
&#xD;
          -  Whole brain radiotherapy within 14 days prior to start of study treatment&#xD;
&#xD;
          -  Stereotactic radiosurgery within 7 days prior to start of study treatment&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study&#xD;
&#xD;
          -  History of or concurrent serious medical condition or abnormality in clinical&#xD;
             laboratory tests that, in the investigator's judgment, precludes the participant's&#xD;
             safe participation in and completion of the study or confounds the ability to&#xD;
             interpret data from the study&#xD;
&#xD;
          -  Incomplete recovery from any surgery prior to the start of study treatment that would&#xD;
             interfere with the determination of safety or efficacy of study treatment&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or higher), myocardial infarction, or cerebrovascular accident within 3&#xD;
             months prior to enrollment, unstable arrhythmias, or unstable angina&#xD;
&#xD;
          -  History of another active cancer within 5 years prior to screening that may interfere&#xD;
             with the determination of safety or efficacy of study treatment with respect to the&#xD;
             qualifying solid tumor malignancy&#xD;
&#xD;
          -  In addition to the general exclusion criteria above, in order to be enrolled in a&#xD;
             treatment cohort of the study, participants must not meet any of the cohort-specific&#xD;
             exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO41932 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>Global-Roche-Genentech-Trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Regional Medical Center at Cancer Treatment Centers of America</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado; Center For Cancer/Blood Disorder</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Srvcs; Helen F Graham Can Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute of Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC; Research</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Alphonsus</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Med Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc.</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryland Hematology &amp; Oncology. P.A.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada - Eastern Avenue</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico; Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center - South Telshore Blvd; Drug Supplies</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastchester Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer and Blood Specialists - Setauket Medical Oncology</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Translational Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barrett Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consultants in Medical Oncology and Hematology</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists - Leesburg</name>
      <address>
        <city>Leesburg</city>
        <state>Pennsylvania</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America; Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>PRISMA Health - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The West Clinic; West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Children'S Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Onc-Central Austin CA Ct</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cook Childrens Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Tyler; Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC; Research Department</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre; St Vincents Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre; Medical Oncology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GHdC Site Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sírio-Libanês</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital A. C. Camargo; Oncologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01509-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Cancer - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre · Victoria Hospital; Department of Medicine</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital, Capital Medical University; Oncological Surgery Department</name>
      <address>
        <city>Beijing City</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun City</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <zip>132013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital - Sichuan University</name>
      <address>
        <city>Chengdu City</city>
        <zip>610047</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan Unvierstiy</name>
      <address>
        <city>Shanghai City</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Medical College of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital Skejby; Institut for Klinisk Medicin, Molekylær Medicinsk afdeling</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie; Oncologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret; Service de Pediatrie</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CENTRE LEON BERARD; Département d'Hématologie et d'Oncologie</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse-Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustave-Roussy (IGR)</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Medizinische Klinik Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie &amp; Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik Kinderheikunde I des Zentrums für Kinder- und Jugendmedizin, Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41066</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTU</name>
      <address>
        <city>Würzburg</city>
        <zip>97078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hong Kong Children's Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital; Department of Clinical Onocology</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus; Oncology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital - Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin MC; Davidof Center - Oncology Institute</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sourasky / Ichilov Hospital; Dept. of Oncology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - IRCCS; Dipartimento di Onco-Ematologia Pediatrica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli IRCCS; UOS Fase 1</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asst Degli Spedali Civili Di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori di Milano; S.C. Oncologia Pediatrica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Pediatriche Adolescenza; Osp. Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Meyer; Centro di Eccellenza di Oncologia ed Ematologia Pediatrica</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13605</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital- Adult Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital- Pediatric Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center- Adult Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center- Pediatric Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prinses Maxima Centrum</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital, Cancer and Blood Research</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital; Dept of Oncology</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPO do Porto; Servico de Oncologia Medica</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PanOncology Trials; Hospital Oncológico, Puerto Rico Medical Center</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital; National University Cancer Institute, Singapore (NCIS)</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu</name>
      <address>
        <city>Esplugues De Llobregas</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra Madrid; Servicio de Oncología</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid. Centro Integral Oncologico Clara Campal; CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel (USB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Bellinzona Medizin Onkologie</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital, Klinik und Poliklinik für Medizinische Onkologie</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne Médecine Oncologie ; Département d'Oncologie médicale - BH09 - Bureau 7</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unversitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital; Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>00704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital; Department of Oncology</name>
      <address>
        <city>Taipei City</city>
        <zip>112201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Linkou; Dept of Oncology</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital; Oncology</name>
      <address>
        <city>Zhongzheng Dist.</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 - 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Sutton)</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Swaziland</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Pralsetinib</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

